HP 200

Drug Profile

HP 200

Alternative Names: Zandopa

Latest Information Update: 05 Jan 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zandu Pharmaceutical Works
  • Developer CMI India [CEASED]; Zandu Pharmaceutical Works
  • Class Antiparkinsonians; Phytotherapies
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 05 Jan 2004 No development reported - Clinical-Phase-Unknown for Parkinson's disease in USA (PO)
  • 04 Sep 2000 Investigation in Parkinson's disease in USA (PO)
  • 04 Sep 2000 Launched for Parkinson's disease in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top